Nadolol (CAS 42200-33-9)
QUICK LINKS
Nadolol is a polar and hydrophilic, non-selective beta blocker, which displays activity against beta-1 and beta-2 receptors. It is known that Nadolol inhibits the release of catecholamines from the adrenal glands. Studies involving murine models of asthma suggest that Nadolol at higher concentrations decreases airway resistance response to the muscarinic agonist methacholine. At lower concentrations, Nadolol has the opposite effect. Research indicates that this is due to the fact that Nadolol at higher amounts decreases the degradation of the beta-2 adrenergic receptor and increase production of the receptor. This receptor inhibition is due to forskolin- stimulated phosphorylation of the beta-2 adrenergic receptor at Ser 262, when applied for 5 minutes. Interestingly, phosphorylation of the receptor is reduced upon application consisting of longer time periods.
Nadolol (CAS 42200-33-9) References
- The effects of acute and chronic nadolol treatment on β2AR signaling in HEK293 cells. | Peng, H., et al. 2011. Naunyn Schmiedebergs Arch Pharmacol. 383: 209-16. PMID: 21225244
- Nadolol for the treatment of infantile hemangioma. | Villalba-Moreno, AM., et al. 2015. Am J Health Syst Pharm. 72: 44-6. PMID: 25511837
- Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. | Leren, IS., et al. 2016. Heart Rhythm. 13: 433-40. PMID: 26432584
- The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. | Misaka, S., et al. 2016. Mol Pharm. 13: 512-9. PMID: 26702643
- Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children. | von Alvensleben, JC., et al. 2017. Pediatr Cardiol. 38: 525-530. PMID: 27995288
- Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. | Zacharias, AP., et al. 2018. Cochrane Database Syst Rev. 10: CD011510. PMID: 30372514
- Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P-Glycoprotein. | Shimazaki, S., et al. 2021. J Clin Pharmacol. 61: 799-805. PMID: 33387374
- Stability of Extemporaneously Compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes. | Walsh, A., et al. 2021. Int J Pharm Compd. 25: 163-168. PMID: 33798116
- Dose response to nadolol in congenital long QT syndrome. | Anys, S., et al. 2021. Heart Rhythm. 18: 1377-1383. PMID: 33905813
- Anti-arrhythmic action of nadolol, a beta-adrenergic receptor blocking agent. | Evans, DB., et al. 1976. Eur J Pharmacol. 35: 17-27. PMID: 3420
- Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. | Tan, HJ., et al. 2021. Phytomedicine. 90: 153623. PMID: 34303263
- Contemporary maternal and fetal outcomes in the treatment of LQTS during pregnancy: Is nadolol bad for the fetus? | Hammond, BH., et al. 2022. Heart Rhythm. 19: 1516-1521. PMID: 35525421
- Clinical pharmacokinetics of nadolol: A systematic review. | Kalsoom, S., et al. 2022. J Clin Pharm Ther. 47: 1506-1516. PMID: 36040016
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nadolol, 1 g | sc-253175 | 1 g | $184.00 |